Debiopharm Announces Results of 2 Key Oncology Programs at AACR Conference
Complete the form below to unlock access to ALL audio articles.
Debiopharm International SA (Debiopharm) has announced that preclinical data on the investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 (FGFR 12,3 inhibitor) will be presented at the 2015 Annual meeting of the American Association for Cancer Research (AACR) taking place in Philadelphia.
“Oncology has and will continue to benefit from combined and targeted therapies. Results from these preclinical studies underscore the potential clinical value of our two anti-cancer targeted therapies” said Dr Nigel McCracken, Vice President, Translational Medicine.
Dr McCracken continued, “Currently both Debio 1143 and Debio 1347 are in Clinical Development and Debiopharm remains committed to exploring new combinations and new indications to provide improved benefit to patients suffering from cancers”.
